HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
PHAT
Phathom Pharmaceuticals Inc
Healthcare Biotechnology · New Jersey, USA · Reports in usd
Market Cap: $824.5M
Market Cap
$824.5M
Enterprise Val
$1.25B
P/E Ratio
-3.73
P/B Ratio
-1.88
Trailing PEG (1Y)
0.05
As Of
Apr 26, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value-$438.2M
Gross Margin86.72%
Profit Margin86.72%
Return on Equity55.14%
Return on Assets-84.78%
Current Ratio1.73
Debt/Equity-1.28
LT Debt/Equity-1.28
Revenue Per Share0.81

Income Statement

Dec 31, 2025
Revenue$57.6M
Cost of Revenue$7.6M
Gross Profit$49.9M
R&D$7.5M
SG&A$48.4M
Operating Expenses$55.9M
Operating Income-$5.9M
Interest Expense$16.4M
Tax Expense$0.00
Net Income-$21.1M
EPS (Basic)$-0.27
EPS (Diluted)$-0.27
EBIT-$4.7M
EBITDA-$4.6M
Consolidated Income-$21.1M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$132.8M
Accounts Receivable$78.1M
Inventory$26.3M
Current Assets$229.0M
LT Investments$0.00
Property, Plant & Equipment$3.7M
Intangibles$0.00
Non-Current Assets$30.2M
Total Assets$259.1M
Accounts Payable$5.0M
Current Debt$648.0K
Current Liabilities$132.0M
LT Debt$561.3M
Non-Current Liabilities$565.3M
Total Liabilities$697.3M
Total Debt$561.9M
Retained Earnings-$1.48B
Shareholder Equity-$438.2M
Shares Outstanding71,138,440

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$5.0M
Investing Cash Flow-$87.0K
Financing Cash Flow-$97.0K
CapEx-$87.0K
Free Cash Flow-$5.1M
Depreciation & Amort.$128.0K
Stock-Based Comp$5.6M
Acquisitions / Disposals$0.00
Investment Activity$0.00
Debt Issued/Repaid$0.00
Equity Issued/Repaid$1.3M
Dividends Paid$0.00
Net Change in Cash-$5.2M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h